Budd-Chiari syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Overview

Measures for the primary prevention of Budd-Chiari syndrome include effective management of predisposing conditions, chronic anticoagulation in patients with underlying hypercoagulable disorder, treat patients with an underlying myeloproliferative disorder with aspirin and hydroxyurea rather than anticoagulants such as warfarin.

Measures for the primary prevention of Budd-Chiari syndrome include:^[1]^[2]

Effective treatment of predisposing conditions
Chronic anticoagulation in patients with underlying hypercoagulable disorder
Treat patients with an underlying myeloproliferative disorder with aspirin and hydroxyurea rather than anticoagulants such as warfarin.

↑ Goel RM, Johnston EL, Patel KV, Wong T (2015). “Budd-Chiari syndrome: investigation, treatment and outcomes”. Postgrad Med J. 91 (1082): 692–7. doi:10.1136/postgradmedj-2015-133402. PMID 26494427.
↑ Darwish Murad S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Leebeek FW, Rosendaal FR, Garcia-Pagan JC, Valla DC, Janssen HL (2009). “Etiology, management, and outcome of the Budd-Chiari syndrome”. Ann. Intern. Med. 151 (3): 167–75. PMID 19652186.